SGLT-2 Inhibitors and Ketoacidosis Risk: What New Data Shows Across Different Conditions

SGLT-2 inhibitors are a class of diabetes medications that work by helping the kidneys remove glucose through urine. They have been approved for type 2 diabetes for years, but doctors have recently begun prescribing them for other conditions, including heart failure and chronic kidney disease, where blood glucose is not monitored as frequently.

A known concern with SGLT-2 inhibitors is their link to diabetic ketoacidosis (DKA)—particularly a form called euglycaemic DKA, where dangerous levels of ketones build up in the blood even when blood sugar remains relatively normal. This makes the condition harder to recognize because high blood sugar is often a warning sign of DKA.

Researchers analyzed reports of adverse events from two large independent drug safety databases: the U.S. Food and Drug Administration's FAERS system (covering 2020 through early 2026) and Japan's JADER database. They looked at whether the ketoacidosis signal remained strong, weakened, or changed as SGLT-2 inhibitors were used in new patient populations.

The analysis found a strong ketoacidosis signal for SGLT-2 inhibitors that was consistent across every condition studied—type 2 diabetes, heart failure, chronic kidney disease, and off-label use in type 1 diabetes. The risk did not weaken as these drugs were prescribed for new indications; instead, it remained robust.

In the U.S. database, SGLT-2 inhibitors were associated with a 67-fold increased likelihood of euDKA compared to other drugs. In the Japanese database, the association was even higher at 112-fold. Importantly, SGLT-2 inhibitors accounted for roughly 86 percent of all euDKA reports in the U.S. system and 92 percent in the Japanese system, even though euDKA represented only a small fraction of overall reports for these medications.

The highest risk appeared in patients using SGLT-2 inhibitors off-label for type 1 diabetes, though the signal remained strong across all groups studied.

The median time from starting an SGLT-2 inhibitor to euDKA onset was about 60 days, with most cases developing relatively early in treatment. This timing suggests that close monitoring in the first weeks and months may be particularly important when these medications are started.

As SGLT-2 inhibitors are increasingly used for heart failure and kidney disease—conditions where blood glucose is not routinely checked—the euDKA risk becomes harder to catch. Unlike in diabetes care, where regular glucose monitoring is standard, patients with heart failure or kidney disease may not have frequent blood sugar checks, making the quiet onset of euDKA more dangerous.

The consistency of this finding across two completely independent reporting systems from different countries strengthens confidence that the signal is real and not a statistical artifact. Both databases were analyzed using the same rigorous methods to identify true safety signals.

The researchers note that ketone-based assessment—checking ketone levels in blood or urine—may be warranted when SGLT-2 inhibitors are prescribed, particularly early in treatment and in patients with symptoms like nausea, vomiting, or difficulty breathing, even if blood sugar appears normal.

Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.